Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca Vaccine May Only Gain EU Approval In Under 70s

Limited Data Creates Conundrum For Regulator

Executive Summary

AZ and the EU are at loggerheads over supplies of the COVID-19 vaccine. On top of that, its marketing authorization will present dilemmas.

You may also be interested in...



After Success Against COVID-19 Variants, Novavax Will File Vaccine First In UK

High efficacy in initial readout is good news for global vaccination, and UK will see first emergency use filing.

EU Approval Verdicts Near For A Bumper Crop Of New Drugs

Novartis, Arvelle, AstraZeneca and Incyte are among a raft of drug sponsors who should find out shortly whether the European Medicines Agency will vote in favor of approving their products for use in the EU.

Coronavirus Update: No Sign Of Agreement In EU's Bitter Row With AstraZeneca Over Vaccine Supplies

The dispute over a likely 60% reduction in supplies of AstraZeneca's COVID-19 vaccine shows no sign of resolution. Meanwhile, Lilly, Vir/GSK team up on COVID-19 antibody combination and Moderna negotiates sale of 100 million additional vaccine doses to US.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL005491

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel